This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Tuesday, January 20, 2015
Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic
Gilead, AbbVie rack up new payer deals, but hep C obstacles loom across the Atlantic January 20, 2015 | By Tracy Staton
The hepatitis C market is breaking new ground all over the place. As payers put the squeeze on Gilead Sciences ($GILD) and AbbVie ($ABBV) for discounts in the U.S., England's National Health Service is delaying a broad rollout of Gilead's blockbuster Sovaldi till July, citing the drug's high cost--an unprecedented move on a treatment already blessed by the country's cost-effectiveness watchdogs.
And with AbbVie's cocktail now approved in Europe and the U.K.--under the brand names Viekirax and Exviera, rather than Viekira Pak like in the U.S.--the two drugmakers will be squaring off there in country-by-country negotiations for coverage.
No comments:
Post a Comment